Connect with us
DAPA Banner

Crypto World

CDC Vaccine Research Blocked by Acting Director

Published

on

CDC Vaccine Research Blocked by Acting Director

The acting CDC director blocked the publication of CDC vaccine research showing COVID-19 vaccine benefits on April 10, citing methodology concerns that experts say reflect a research design used in vaccine effectiveness studies for decades.

Summary

  • The acting CDC director blocked a research paper demonstrating COVID-19 vaccine benefits from being published.
  • Experts say the study’s methodology is a long-established standard for measuring vaccine effectiveness.
  • The move has drawn immediate backlash from the scientific and medical communities as the latest instance of administration interference with public health data.

A decision by the acting director of the Centers for Disease Control and Prevention to block a vaccine effectiveness study from publication has drawn sharp condemnation from researchers and public health experts on April 10. The intervention is being characterized as part of a broader pattern of the administration interfering with the release of government-funded scientific findings.

According to Democracy Now!, the acting CDC director blocked a study demonstrating the benefits of COVID-19 vaccines from publication, citing concerns about the research methodology. Experts responded immediately, noting the design used in the blocked study is the same approach that has been standard practice in vaccine research for decades.

Advertisement

Blocking the study removes from public record data developed using federal resources. Public health researchers described the intervention as highly irregular, noting that methodological disputes are normally addressed through peer review, not by preventing publication entirely.

The Scientific and Medical Backlash

Multiple researchers and public health officials said publicly on April 10 that suppressing vaccine effectiveness data poses direct risks to the clinical and policy decisions that rely on CDC-published evidence. Vaccine protocols at hospitals, clinics, and public health agencies are calibrated against published CDC data, and blocking a study denies practitioners access to evidence they would otherwise use.

The decision has drawn comparisons to other recent cases of the administration restricting data-related activities for political reasons. Anthropic sued the US government in March after alleging retaliation for refusing certain military uses of its technology, with the company arguing the government was using legal mechanisms to restrict information and capabilities that conflicted with its preferences.

Advertisement

A Pattern of Data Interference

Critics say the CDC decision is not an isolated event but part of a consistent approach by the administration to control what scientific information enters the public domain. The acting director offered no alternative process by which the blocked findings could be reviewed and eventually published.

As crypto.news reported, the administration has simultaneously been accelerating the deployment of AI tools across federal agencies, raising questions among civil liberties advocates about who decides what information government agencies produce, share, and suppress.

Source link

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

Bitwise Added Ticker $BHYP and a 0.67% Management Fee In Its Latest Filing

Published

on

Bitwise Added Ticker $BHYP and a 0.67% Management Fee In Its Latest Filing

Bitwise Asset Management has reportedly taken a key step toward launching its proposed spot Hyperliquid exchange-traded fund, filing a second amendment with the US Securities and Exchange Commission.

In an X post on Friday, Bloomberg senior ETF analyst Eric Balchunas highlighted that Bitwise had updated its Hyperliquid ETF to include the ticker $BHYP and had also set a management fee of 0.67% (67 basis points).

According to Balchunas, the filing of these details generally indicates that the product will “launch soon.”

“HYPE is up 200% in the past year,” he said, adding that the firm was likely “trying to strike” while the iron was “hot.”

Advertisement

The filing comes amid competition from other asset managers vying to launch the first spot ETF tied to the crypto perpetual futures protocol and blockchain, with Grayscale and 21Shares also pushing for similar products of their own.

Bitwise was the first of the three to submit a Hyperliquid ETF filing with the SEC in September. 21Shares followed a month later with its own, while Grayscale submitted its filing in late March.

Source: Eric Balchunas 

If approved, Bitwise’s ETF will trade on the NYSE Arca stock exchange and offer investors exposure to the spot price of Hyperliquid.

In the firm’s first filing amendment from December, Bitwise also indicated that the fund would seek to generate additional returns from HYPE staking — something Grayscale and 21Shares haven’t explicitly indicated their funds would do.

Hyperliquid continues to gain traction

According to data from CoinGecko, the price of HYPE is up 65% since the start of 2026 to around $41.96 at the time of writing, despite a tough start to the year for the broader crypto market. Over 12 months, the price of HYPE is also up about 182%.

Advertisement

Related: BlackRock Bitcoin ETF sees $269M inflows, best day since early March

Alongside a strong token performance, blockchain analytics platform CoinGlass reported in early April that Hyperliquid had broken into the top 10 crypto derivatives platforms by volume, joining the likes of Binance, OKX and Bybit.

During Q1, Hyperliquid generated $492.7 billion in trading volume, putting it shy of ninth-placed Coinbase by about $90 billion.

Magazine: Should users be allowed to bet on war and death in prediction markets?

Advertisement